Artrya FY26 Net Loss $25.2m, Three US Customers Signed

Artrya (ASX:AYA) released its FY26 financial results and operational update presentation for the year ended 30 June 2026. Statutory revenue was $28,000, the same as FY25, after a $149,000 accounting adjustment to revenue of $177,000 that the company attributed to the non-cash impact of foundation partner options. Other income, which Artrya described as the research and development rebate received and accrued at year end, was $5.647 million. On the management presentation, total expenses rose to $24.665 million from $18.777 million for an operating EBITDA loss of $18.990 million, a measure that excludes depreciation and amortisation of $1.255 million, share-based payments of $1.402 million and a $5.945 million other non-cash expense; on a statutory basis total expenses were $33.275 million and the operating loss $27.600 million. Net loss after tax was $25.183 million against $16.406 million in FY25. Artrya said contractors and consultants increased with development of Salix modules and regulatory submission, and that employee benefits reflected growing headcount to support expansion into the United States. It said the other non-cash expense relates to the conversion of US foundation partners to commercial customers, which triggered accounting for the vesting of affiliate options, creating non-cash charges to both revenue and expenses over four years without affecting cash receipts, the same treatment behind the $149,000 revenue adjustment.

Artrya reported what it presented as cash of $74.0 million and nil debt at 30 June 2026, and said $80.0 million of funding was secured during FY26; its balance sheet shows cash and cash equivalents of $44.025 million and other investments of $30.149 million. It reported finance income and foreign exchange gains of $2.410 million on the management presentation, against statutory finance income of $2.434 million, and attributed the line to interest income on $30 million of term deposits held following the capital raise during the year. The company said it secured three commercial United States customers in FY26: Tanner Health, live and generating revenue with five hospitals fully integrated under a five-year contract; Northeast Georgia Health System, on a three-year contract with one hospital fully integrated and all hospitals live expected by the second quarter of FY27; and Cone Health, on a five-year contract with integration underway and full integration expected by the second quarter of FY27. Artrya said Northeast Georgia Health System went live clinically in July 2026 and that Cone Health will go live shortly. It also said its SAPPHIRE study, which it describes as a multicentre retrospective study, is underway with six large United States health systems confirmed as participants, and that having all six active in Phase 1 is an FY27 objective. Artrya received FDA clearance for Salix Coronary Plaque in August 2025 and said clearance for Salix Coronary Flow, which is not yet cleared, is targeted by the end of 2026.